Meeting
2017 ASCO Annual Meeting
A phase II study (KSCC/HGCSG/CCOG/PerSeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer.
Authors
Katsunori Shinozaki
Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan
Katsunori Shinozaki , Satoshi Yuki , Tomomi Kashiwada , Tetsuya Kusumoto , Masaaki Iwatsuki , Hironaga Satake , Kazuma Kobayashi , Taito Esaki , Yuichiro Nakashima , Nobuhide Kubo , Shoji Tokunaga , Takayuki Shimose , Akitaka Makiyama , Hiroshi Saeki , Eiji Oki , Hideo Baba , Yoshihiko Maehara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
000017552
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4059)
DOI
10.1200/JCO.2017.35.15_suppl.4059
Abstract #
4059
Poster Bd #
51
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.
First Author: Jifang Gong
Poster
2014 Gastrointestinal Cancers Symposium
Phase II study of trastuzumab in combination with capecitabine and oxaliplatin in patients with advanced gastric cancer.
First Author: Min-Hee Ryu
Poster
2013 ASCO Annual Meeting
A phase ll study of new combination regimen with trastuzumab, S-1, and CDDP in HER2-positive advanced gastric cancer (HERBIS-1).
First Author: Keisuke Koeda
Poster
2013 Gastrointestinal Cancers Symposium
A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1).
First Author: Naotoshi Sugimoto